Evidence map›Paper›PMID 41729075›Full record

ArticleJCI insight2026

Characterization of the clonal hierarchy and immunophenotype of PTPN11 mutations in acute myeloid leukemia.

Sydney Fobare, Chia Sharpe, Kate Quinn, Kinsey Bryant, Linde A Miles, Robert L Bowman, Carolyn Cheney, Casie Furby, Marissa Long, Kaytlynn Fyock and 21 more

Abstract read
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Sydney FobareMedical Scientist Training Program, The Ohio State University, Columbus, Ohio, USA.
Chia SharpeDepartment of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Kate QuinnDepartment of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Kinsey BryantDepartment of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Linde A MilesDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital, Cincinnati, Ohio, USA.
Robert L BowmanDepartment of Cancer Biology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Carolyn CheneyDepartment of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Casie FurbyDepartment of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Marissa LongDepartment of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Kaytlynn FyockDepartment of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Ben WronowskiDepartment of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
James R LermaDepartment of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Krzysztof MrózekClara D. Bloomfield Center for Leukemia Outcomes Research, and.
Deedra NicoletClara D. Bloomfield Center for Leukemia Outcomes Research, and.
Thomas M SesterhennDepartment of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Megan E JohnstoneDepartment of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Jianmin PanBiostatistics and Informatics Shared Resource, University of Cincinnati Cancer Center, Cincinnati, Ohio, USA.
Shesh N RaiBiostatistics and Informatics Shared Resource, University of Cincinnati Cancer Center, Cincinnati, Ohio, USA.
Chandrashekhar PasareDepartment of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Nives ZimmermannPathology and Laboratory Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Wen-Mei YuAflac Cancer and Blood Disorders Center, Department of Pediatrics, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA.
Cheng-Kui QuAflac Cancer and Blood Disorders Center, Department of Pediatrics, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA.
Andrew CarrollDepartment of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Richard StoneDana-Farber/Partners CancerCare, Boston, Massachusetts, USA.
Eunice S WangRoswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Jonathan KolitzMonter Cancer Center, Zucker School of Medicine at Hofstra/Northwell, Lake Success, New York, USA.
Bayard PowellWake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, USA.
John P PerentesisCancer and Blood Diseases Institute, Cincinnati Children's Hospital, Cincinnati, Ohio, USA.
Ann-Kathrin EisfeldClara D. Bloomfield Center for Leukemia Outcomes Research, and.
Erin HertleinDepartment of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
John C ByrdDepartment of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
Targeted Therapy for LeukemiaR35CA197734 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2015 to 2021
$6.6M
ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" TherapiesUG1CA233338 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2019 to 2025
$4.5M
The role of PTPN11 and NPM1 mutations in acute myeloid leukemia development and therapy resistanceF30CA265281 · NCI · UNIVERSITY OF CINCINNATI · PI FOBARE, SYDNEY · 2021 to 2025
$196k
NCI NIH HHS F30 CA265281NCI NIH HHS P30 CA016058NCI NIH HHS R35 CA197734NCI NIH HHS UG1 CA233338
6 · The paper itself

Abstract

Mutations in protein tyrosine phosphatase non-receptor type 11 (PTPN11) have been considered late acquired mutations in acute myeloid leukemia (AML) development. Using single-cell DNA sequencing, we found that PTPN11 mutations can occur as initiating events in some patients with AML when accompanied by strong oncogenic drivers, commonly NPM1 mutations. The resulting AML has a diverse set of variably differentiated myeloid cells with few myeloid cells that lack leukemic mutations. The role of Ptpn11 as a codriver was confirmed in a murine model that exhibits an AML phenotype with a comparable immune diversity that is serially engraftable and reconstituted from early precursor cells. Furthermore, lineage-negative bone marrow cells from these mice reconstitute the full diversity of mature myeloid cells, and these cells exhibit an altered cytokine response after physiologic stimulation. Our work highlights how PTPN11-mutated AML is derived from a multitude of codominant and late acquired aberrations that have a previously unrecognized differentiated myeloid clonal expansion potentially contributing to pathogenesis of the disease.

Indexed as

Leukemia, Myeloid, AcuteMyeloid CellsNucleophosminProtein Tyrosine Phosphatase, Non-Receptor Type 11AdultAgedAnimalsBone MarrowBone Marrow CellsCarcinogenesisDisease Models, AnimalDNA Mutational AnalysisFemaleHumansImmunophenotypingMaleNPM1 protein, humanNpm1 protein, mouseNucleophosminProtein Tyrosine Phosphatase, Non-Receptor Type 11PTPN11 protein, humanPtpn11 protein, mouseHematologyLeukemiasMolecular geneticsMouse modelsOncology

Identifiers

PMID41729075
PMCPMC12956013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.